Literature DB >> 21617141

Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy.

Sridevi Devaraj1, Peter Tobias, Balakuntalam S Kasinath, Rajendra Ramsamooj, Alaa Afify, Ishwarlal Jialal.   

Abstract

OBJECTIVE: Type 1 diabetes (T1DM) is a proinflammatory state and confers an increased risk for vascular complications. Toll-like receptors (TLR) could participate in diabetic vasculopathies. Whether TLR activation contributes to the proinflammatory state of T1DM and the pathogenesis of diabetic nephropathy remains unknown. METHODS AND
RESULTS: We induced T1DM in TLR2 knockout mice (TLR2-/-) and wild-type littermates (C57BL/6J-WT) using streptozotocin (STZ). Fasting blood, peritoneal macrophages, and kidneys were obtained for flow cytometry, Western blot, microscopy, and cytokine assays at 6 and 14 weeks after induction of diabetes. Macrophage TLR2 expression and MyD88-dependent signaling were increased in diabetic mice (WT+STZ) compared with nondiabetic WT mice. These biomarkers were attenuated in diabetic TLR2-/- macrophages. WT+STZ mice showed increased kidney:body weight ratio due to cell hypertrophy, increased albuminuria, decreased kidney nephrin, podocin, and podocyte number and increased transforming growth factor-β and laminin compared with WT mice. Nephrin, podocin, and podocyte number and effacement were restored, and transforming growth factor-β and laminin levels were decreased in TLR2-/-+ STZ mice kidneys versus WT+STZ. Peritoneal and kidney macrophages were predominantly M1 phenotype in WT+STZ mice; this was attenuated in TLR2-/-+STZ mice.
CONCLUSIONS: These data support a role for TLR2 in promoting inflammation and early changes of incipient diabetic nephropathy, in addition to albuminuria and podocyte loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617141      PMCID: PMC3148786          DOI: 10.1161/ATVBAHA.111.228924

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  56 in total

Review 1.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

2.  Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse.

Authors:  Mohammad K Mohammad; Michael Morran; Brandon Slotterbeck; Douglas W Leaman; Yaping Sun; Hermann von Grafenstein; Soon-Cheol Hong; Marcia F McInerney
Journal:  Int Immunol       Date:  2006-05-25       Impact factor: 4.823

3.  Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.

Authors:  C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

4.  C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype.

Authors:  Sridevi Devaraj; Ishwarlal Jialal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-17       Impact factor: 8.311

5.  Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury.

Authors:  Yasushi Sakata; Jian-Wen Dong; Jesus G Vallejo; Chien-Hua Huang; J Scott Baker; Kevin J Tracey; Osamu Tacheuchi; Shizuo Akira; Douglas L Mann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-15       Impact factor: 4.733

Review 6.  The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.

Authors:  S Chen; S W Hong; M C Iglesias-de la Cruz; M Isono; A Casaretto; F N Ziyadeh
Journal:  Ren Fail       Date:  2001 May-Jul       Impact factor: 2.606

7.  Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started.

Authors:  Ariela Benigni; Carla Zoja; Marco Campana; Daniela Corna; Fabio Sangalli; Daniela Rottoli; Elena Gagliardini; Sara Conti; Steve Ledbetter; Giuseppe Remuzzi
Journal:  Nephron Exp Nephrol       Date:  2006-08-10

8.  Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats.

Authors:  C Sassy-Prigent; D Heudes; C Mandet; M F Bélair; O Michel; B Perdereau; J Bariéty; P Bruneval
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

Review 9.  Nephrin-signature molecule of the glomerular podocyte?

Authors:  Gavin I Welsh; Moin A Saleem
Journal:  J Pathol       Date:  2010-02       Impact factor: 7.996

10.  High glucose induces toll-like receptor expression in human monocytes: mechanism of activation.

Authors:  Mohan R Dasu; Sridevi Devaraj; Ling Zhao; Daniel H Hwang; Ishwarlal Jialal
Journal:  Diabetes       Date:  2008-07-23       Impact factor: 9.461

View more
  59 in total

1.  Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1.

Authors:  Jenny E Kanter; Farah Kramer; Shelley Barnhart; Michelle M Averill; Anuradha Vivekanandan-Giri; Thad Vickery; Lei O Li; Lev Becker; Wei Yuan; Alan Chait; Kathleen R Braun; Susan Potter-Perigo; Srinath Sanda; Thomas N Wight; Subramaniam Pennathur; Charles N Serhan; Jay W Heinecke; Rosalind A Coleman; Karin E Bornfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.

Authors:  Ishwarlal Jialal; Harmeet Kaur
Journal:  Curr Diab Rep       Date:  2012-02-08       Impact factor: 4.810

Review 3.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

4.  Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy.

Authors:  Harmeet Kaur; Alexander Chien; Ishwarlal Jialal
Journal:  Am J Physiol Renal Physiol       Date:  2012-08-08

5.  Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.

Authors:  Ming-Zhi Zhang; Xin Wang; Haichun Yang; Agnes B Fogo; Brian J Murphy; Robert Kaltenbach; Peter Cheng; Bradley Zinker; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

6.  Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney.

Authors:  Michaele B Manigrasso; Richard A Friedman; Ravichandran Ramasamy; Vivette D'Agati; Ann Marie Schmidt
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-22

Review 7.  Renal fibrosis: Primacy of the proximal tubule.

Authors:  Leslie S Gewin
Journal:  Matrix Biol       Date:  2018-02-06       Impact factor: 11.583

Review 8.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

Review 9.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

10.  Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.

Authors:  Jin Ma; Huiling Wu; Cathy Y Zhao; Usha Panchapakesan; Carol Pollock; Steven J Chadban
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.